-
PD-1 First Tier Revenue Rankings Are Big Open! What is the commercialization capability of innovative pharmaceutical companies?
Time of Update: 2020-11-17
Xinda Bio's Xindili single resistance is the second approved domestic PD-1, which was approved at the end of 2018, the first year of commercialization in 2019 to achieve sales of more than 1 billion yuan, 2020 after the inclusion of health insurance price reduction, still achieved rapid growth, sales of 921 million yuan in the first half of the year, close to last year's full-year data, growth rate of 177%.
-
PD-1 First Tier Revenue Rankings Are Big Open! What is the commercialization capability of innovative pharmaceutical companies?
Time of Update: 2020-09-23
Xinda Bio's Xindili single resistance is the second approved domestic PD-1, which was approved at the end of 2018, 2019, the first year of commercialization to achieve sales of more than 1 billion yuan, 2020 after the inclusion of health insurance price reduction, still achieved rapid growth, sales of 921 million yuan in the first half of the year, close to last year's full-year data, growth rate of 177%.
-
What new options are available for new drugs for Hodgkin's lymphoma after the PD-1 antibody fight?
Time of Update: 2020-08-03
at the 2019 International Conference on Malignant Lymphoma (ICML), published the results of ib trials conducted jointly by AFM13 and Pembro for R/R cHL patients, with the middle of 30 patients in the group receiving 4-line treatment, with an ORR of 88%, of which CR reached 46%.
-
What new options are available for new drugs for Hodgkin's lymphoma after the PD-1 antibody fight?
Time of Update: 2020-07-29
Adcetris (Vibutuxixmonodis) was approved for listing in China, the three domestic PD-1 antibody drugs with Hodgkin's lymphoma as the initial indications, PD-1 antibodies or other have a chance to brea
-
What about the once-buzzing PD-1?
Time of Update: 2020-06-01
Since pD-1/PD-L1, an important target of cancer immunotherapy, has been discovered, it has been entrusted with the important mission of fighting cancer, and industry, capital, and even society as a wh
-
What about K-drug sales of more than $10 billion PD-(L)1 drug sales in 2019?
Time of Update: 2020-05-30
To date, a total of 10 PD-(L)1 cancer immunotherapy drugs have been available worldwide, including four domestic and six multinational pharmaceutical companies: BMS's Opdivo, Mercado's Keytruda, AZ's
-
What about K-drug sales of more than $10 billion PD-(L)1 drug sales in 2019?
Time of Update: 2020-05-13
to date, a total of 10 PD-(L)1 cancer immunotherapy drugs have been available worldwide, including four domestic and six multinational pharmaceutical companies: BMS's Opdivo, Mercado's Keytruda, AZ'
-
What are the first signs of PD-1 liver cancer in China? Whose green card did you turn this time?
Time of Update: 2020-01-13
Recently, Hengrui medicine (600276-cn) released a news on its official website Its independently developed new drug, Arica ® (arizumab) combined with aitan ® (apatinib), has been included in the natio
-
What's the right thing to do to give up PD-1 and sell coagulation factor Ⅷ, a star company going to Hong Kong for IPO?
Time of Update: 2019-11-21
On November 17, Corning Jerry was listed on the Hong Kong stock exchange This is the substantial progress the company has made since it submitted its IPO application in July As the 17th biotech compan
-
Give up PD-1, sell coagulation factor Ⅷ, what's the star company doing right? |Medical line observation
Time of Update: 2019-11-21
On November 17, Corning Jerry was listed on the Hong Kong stock exchange This is the substantial progress the company has made since it submitted its IPO application in July As the 17th biotech compan
-
What's the status of PD-1?
Time of Update: 2019-10-30
Original: Mumu Since PD-1 / PD-L1, an important target of tumor immunotherapy, has been found, it has shouldered the important mission of human beings to defeat cancer Industry, capital and even the w
-
K and O drugs bet on the first-line treatment of lung cancer. Local PD-1. What were the results of the first half of the year?
Time of Update: 2019-10-28
In the past half a year, with more indications of PD-1 first tier products approved one after another, the momentum of seizing cities and land is growing, and the competition pattern in the field of P
-
K and O drugs bet on the first-line treatment of lung cancer. Local PD-1. What were the results of the first half of the year?
Time of Update: 2019-10-27
In the past half a year, with more indications of PD-1 first tier products approved one after another, the momentum of seizing cities and land is growing, and the competition pattern in the field of P
-
Domestic PD-1 has applied for listing one after another: what is the effect?
Time of Update: 2018-04-25
Source: Medical magic cube data on April 23, 2017, the State Food and Drug Administration reported that the PD-1 antibody of Hengrui company had submitted an application for listing Up to now, five PD
-
PD-1 inhibitor has become an "anti-cancer artifact", what is the progress of domestic and foreign enterprises
Time of Update: 2015-07-20
Source: biodiscovery 2015-7-20 with immunotherapy sweeping the field of cancer treatment, PD-1 inhibitor has become one of the most dazzling heavyweight drugs Among them, the most famous are opdivo (n